{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated/Withdrawn" in comments (approximate match)
Status:
Investigational
Source:
NCT02564744: Phase 2 Interventional Completed Diffuse Large B-Cell Lymphoma
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03708224: Phase 2 Interventional Recruiting Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03943290: Phase 2 Interventional Terminated Facioscapulohumeral Muscular Dystrophy
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03587311: Phase 2 Interventional Active, not recruiting Fallopian Tube Endometrioid Adenocarcinoma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02545504: Phase 3 Interventional Completed Gastric Adenocarcinoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02202759: Phase 2 Interventional Terminated Adenocarcinoma of the Stomach
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exbivirumab [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT02785900: Phase 3 Interventional Terminated Acute Myeloid Leukemia
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03061812: Phase 3 Interventional Completed Small Cell Lung Cancer
(2017)
Source URL:
Class:
PROTEIN
